Stock Research Archive

AppLovin has collapsed 60.6% from its $738.01 high to sit exactly on its 52-week low of $290.36, despite delivering Q1 +59% to $1.84B and Q2 +53% to $1.924B revenue growth with 83.8% adjusted EBITDA margins, ~61% net margins and ~$3.9B free cash flow. The derating was driven by a slight Q2 revenue m...

Iovance has executed a genuine commercial turnaround: Amtagvi, the first FDA-approved autologous TIL therapy for solid tumors, drove Q2 2026 revenue of $99.3M (+66% YoY, +51% QoQ to $91M for Amtagvi), gross margin inflection to 56% from 41%, and a 57% reduction in net loss to $47.3M. Management rais...

Fair Isaac has collapsed 69% from its $1998 high to $617.87 after the FHFA on Sept 4, 2026 directed Fannie Mae and Freddie Mac to accept VantageScore 4.0, ending FICO's de facto mortgage monopoly. The move, amplified by FHFA Director Pulte's pricing criticism of ~1800% cumulative price hikes since 2...

Wheels Up Experience (UP) at $3.58 is a classic distressed turnaround option: down 91.7% from its $43.00 52-week high, post 1-for-20 reverse split in April 2026 to save its NYSE listing, with a $129.87M market cap against ~$700-800M of shrinking revenue. The operating story has stabilized at the edg...

Eversource Energy at $63.28 sits at its 52-week low, down 17.4% from $76.57, pricing in a regulatory reset and the hangover from its failed offshore wind expansion. Q2 2026 crystallized the cleanup: GAAP EPS of $0.14 vs $0.96 a year ago on a $164M after-tax offshore wind contingent charge ($0.43) an...

Allstate delivered exceptional Q2 2026 results — $18.6B revenue (+11.8% y/y), $3.2B net income, $2.3B adjusted net income ($8.99/share), combined ratio improved 4.5 pts to 86.6%, and net investment income +33.8% to $1.0B — yet the stock has sold off 17.9% from its $277.22 high to $227.55 and fell 4....

Kodiak Sciences (KOD) was transformed on Sept 28, 2026 when both Zenkuda (tarcocimab tedromer) and tabirafusp alfa (KSI-501) met primary endpoints in the Phase 3 DAYBREAK wet AMD trial vs Regeneron's Eylea, triggering a +178% single-day surge to $89.92 on 38.5M shares. Zenkuda matched or beat aflibe...

Deutsche Bank has delivered the proof point skeptics demanded for a decade: H1 2026 post-tax profit of EUR4.1bn, the highest half-year ever, with 11.9% post-tax ROTE, 60.9% cost/income, 13.9% CET1 and EUR17.2bn revenue tracking to its EUR33bn full-year ambition. Q2 net attributable profit rose 10.5%...

ARMOUR Residential REIT (ARR) is a highly levered agency mREIT trading at its 52-week low ($13.98 vs $13.76 low, -27.6% from high) with an RSI of 20.2 and a ~20.6% dividend yield ($0.24 monthly). Q2 2026 looked stable on the surface — $114.8M GAAP net income ($0.86/share, $0.72 core) on $263.9M reve...

MongoDB has fundamentally improved since our March bear call at $246.54 — Q2 FY27 delivered 30.5% revenue growth to $771.8M, 90% non-GAAP EPS growth to $1.90, 122% net ARR expansion, 91% RPO growth, and GAAP profitability ($40.9M net income). Atlas grew 29% for the fifth straight quarter and Enterpr...

Akamai has signed a transformative $11.6B 7-year cloud infrastructure deal with Anthropic, ramping to $1.7B annually by 2028 with an option to $20B. Against a $15.87B market cap and ~$4.4B annualized revenue base, this is company-defining backlog that shifts Akamai from ex-CDN value trap to contract...

Jaguar Health (JAGX) is a $3.67M micro-cap commercial-stage biotech trading at $7.70, down 99.3% from its $1,164.50 52-week high and up 228% from its $2.35 low after a speculative 1,585% spike on September 23 on news FDA waived 2027 fees. The spike masks terrible fundamentals: its lead crofelemer Ph...

Agora (API) has quietly engineered a fundamental turnaround: seven consecutive quarters of GAAP profitability through Q2 2026, accelerating revenue growth from 12% (Q3 2025) to 13.5% (Q1 2026) to 18% ($40M in Q2 2026), and its first full year of profitability since 2018. The headline is a two-track ...

Infleqtion (INFQ) is a newly public (Feb-26 SPAC) neutral-atom quantum company with a genuinely differentiated story: real quantum revenue ($23.4M H1, ~$45.1M FY26 guidance, Q2 +116% y/y), dual sensing + computing lines, active defense contracts in three countries, a $20M NASA follow-on, Nvidia part...

Greenland Energy (GLND) is a pre-revenue, exploration-stage Arctic oil promoter that spiked 66% in one session to $5.35 on 166M shares (~6x its stated market cap in dollar volume) after a U.S.-Greenland security pact headline. The move extends a pattern of hype-driven volatility: the stock is still ...

Arm Holdings has transformed its narrative from a 22%-growth IP royalty company into an AI-compute story, with data-center royalties more than doubling, IDC showing Arm overtaking x86 in AI servers ($53B accelerated server value in Q1), and a $2B pipeline for its new AGI CPU launched in March 2026. ...

Moderna has staged one of the most violent biotech repricings in recent history, up ~400% YTD to $194.82, just 0.5% below its $195.71 52-week high from a $22.28 low. The driver is real: individualized neoantigen therapy intismeran autogene with Merck's Keytruda met primary and key secondary endpoint...

Costco remains the best operator in global retail, and FQ4 FY2026 proved it again: $95.72B total revenue (+11.1% YoY) beat $94.86B consensus, adjusted EPS $6.75 (+15%) beat, net sales $93.9B (+11.3%) with 10.7% comps, net income +12.3% to $2.61B on record gas volumes and tariff refunds. Renewal rate...

Maison Solutions (MSS) has collapsed 98.9% from its $198 52-week high to $2.10, and the fundamentals explain why: a shrinking core grocery base, a 1-for-5 reverse split on July 22, 2026, ongoing IPO fraud / related-party allegations and derivative litigation, and a last-minute pivot to a Maison AI p...

Chemours (CC) at $14.74 is a classic post-hype unwind: up 120%+ in early 2026 on AI/data-center and Opteon refrigerant euphoria to ~$28.67, then down 48.6% after a disastrous Q2 2026 (revenue $1.59B vs $1.66B expected, adjusted EPS down 31% to $0.42, $65M sales misallocation) and a $25-75M cut to fu...